InfuSystem Holdings Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Rich DiIorio

Algemeen directeur

US$2.3m

Totale compensatie

Percentage CEO-salaris	26.2%
Dienstverband CEO	7yrs
Eigendom CEO	2.1%
Management gemiddelde ambtstermijn	4.9yrs
Gemiddelde ambtstermijn bestuur	3yrs

Recente managementupdates

Recent updates

Is It Time To Consider Buying InfuSystem Holdings Inc. (NYSEMKT:INFU)?

Mar 29

Analyse CEO-vergoeding

Hoe is Rich DiIorio's beloning veranderd ten opzichte van InfuSystem Holdings's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	US$1m
Jun 30 2024	n/a	n/a	US$366k
Mar 31 2024	n/a	n/a	US$84k
Dec 31 2023	US$2m	US$600k	US$872k
Sep 30 2023	n/a	n/a	US$907k
Jun 30 2023	n/a	n/a	US$661k
Mar 31 2023	n/a	n/a	US$62k
Dec 31 2022	US$2m	US$600k	US$18k
Sep 30 2022	n/a	n/a	US$298k
Jun 30 2022	n/a	n/a	-US$593k
Mar 31 2022	n/a	n/a	US$391k
Dec 31 2021	US$2m	US$550k	US$1m
Sep 30 2021	n/a	n/a	US$12m
Jun 30 2021	n/a	n/a	US$15m
Mar 31 2021	n/a	n/a	US$18m
Dec 31 2020	US$3m	US$450k	US$17m
Sep 30 2020	n/a	n/a	US$7m
Jun 30 2020	n/a	n/a	US$6m
Mar 31 2020	n/a	n/a	US$2m
Dec 31 2019	US$606k	US$339k	US$1m
Sep 30 2019	n/a	n/a	US$281k
Jun 30 2019	n/a	n/a	-US$1m
Mar 31 2019	n/a	n/a	-US$2m
Dec 31 2018	US$1m	US$312k	-US$1m
Sep 30 2018	n/a	n/a	-US$19m
Jun 30 2018	n/a	n/a	-US$18m
Mar 31 2018	n/a	n/a	-US$19m
Dec 31 2017	US$635k	US$235k	-US$21m

Compensatie versus markt: De totale vergoeding ($USD 2.29M ) Rich } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.47M ).

Compensatie versus inkomsten: De vergoeding van Rich is het afgelopen jaar met meer dan 20% gestegen.

CEO

Rich DiIorio (49 yo)

7yrs

Tenure

US$2,286,657

Compensatie

Mr. Richard A. DiIorio, also known as Rich, joined InfuSystem Holdings Inc. in 2004 and serves as its Chief Executive Officer and Director since November 15, 2017. He served as President at InfuSystem Hold...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Richard DiIorio	CEO & Director	7yrs	US$2.29m	2.14% $ 4.2m
Carrie Lachance	President	5.1yrs	US$1.26m	0.86% $ 1.7m
Barry Steele	Executive VP & CFO	4.7yrs	US$1.15m	0.33% $ 648.6k
Addam Chupa	Executive VP & Chief Information Officer	no data	geen gegevens	0.17% $ 343.7k
Jerod Funke	Executive VP & Chief HR Officer	1.1yrs	geen gegevens	0.046% $ 90.8k
Jeanie Latz	Corporate Secretary	no data	geen gegevens	geen gegevens

4.9yrs

Gemiddelde duur

49yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van INFU wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Richard DiIorio	CEO & Director	7yrs	US$2.29m	2.14% $ 4.2m
Carrie Lachance	President	3.5yrs	US$1.26m	0.86% $ 1.7m
Scott Shuda	Independent Chairman of the Board	8.2yrs	US$196.73k	0.48% $ 942.4k
Beverly Huss	Director	less than a year	geen gegevens	0.020% $ 39.7k
Ralph Boyd	Independent Director	2.5yrs	US$167.41k	0.028% $ 55.4k
Ronald Hundzinski	Independent Director	no data	geen gegevens	geen gegevens
Paul Gendron	Independent Director	5.5yrs	US$179.59k	0.31% $ 600.6k
Kenneth Eichenbaum	Director	less than a year	geen gegevens	0.019% $ 37.0k

3.0yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van INFU wordt beschouwd als ervaren (gemiddelde ambtstermijn 3 jaar).

InfuSystem Holdings Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

InfuSystem Holdings, Inc. Appoints Ronald Hundzinski to the Board of Directors

Insider exercised options and sold US$54k worth of stock

CEO & Director exercised options and sold US$142k worth of stock

Less than half of directors are independent

InfuSystem Holdings, Inc. Approves Directorate Elections

InfuSystem Holdings, Inc., Annual General Meeting, May 16, 2024

Recent updates

InfuSystem Holdings, Inc. Appoints Ronald Hundzinski to the Board of Directors

New minor risk - Share price stability

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Infusystem Holdings, Inc. Provides Revenue Guidance for the Full Year 2024

Insider exercised options and sold US$54k worth of stock

InfuSystem Holdings, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Price target decreased by 11% to US$14.17

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Infusystem Holdings, Inc. Reaffirms Earnings Guidance for the Full Year 2024

InfuSystem Holdings, Inc. to Report Q2, 2024 Results on Aug 08, 2024

CEO & Director exercised options and sold US$142k worth of stock

Less than half of directors are independent

InfuSystem Holdings, Inc. (NYSEAM:INFU) announces an Equity Buyback for $20 million worth of its shares.

InfuSystem Holdings, Inc. Approves Directorate Elections

InfuSystem Holdings, Inc. Reaffirms Earnings Guidance for the Full Year 2024

InfuSystem Holdings, Inc. to Report Q1, 2024 Results on May 09, 2024

InfuSystem Holdings, Inc., Annual General Meeting, May 16, 2024

InfuSystem Receives Notice from NYSE American Regarding Late Filing of Annual Report on Form 10-K

InfuSystem Holdings, Inc. announced delayed annual 10-K filing

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

InfuSystem Holdings, Inc. Announces Resignation of R. Rimmy Malhotra as Member of the Board

InfuSystem Holdings, Inc. to Report Q4, 2023 Results on Mar 14, 2024

New minor risk - Shareholder dilution

InfuSystem Holdings, Inc. Provides Revenue Guidance for the Fourth Quarter of 2023

InfuSystem Holdings, Inc. to Report Q3, 2023 Results on Nov 07, 2023

CEO & Director exercised options and sold US$870k worth of stock

Consensus EPS estimates fall by 25%, revenue upgraded

InfuSystem Holdings, Inc. Revises Earnings Guidance for the Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Now 20% undervalued

InfuSystem Holdings, Inc. to Report Q2, 2023 Results on Aug 03, 2023

President exercised options and sold US$79k worth of stock

Independent Director notifies of intention to sell stock

Now 20% undervalued after recent price drop

Now 21% undervalued after recent price drop

Consensus EPS estimates fall by 15%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

InfuSystem Holdings, Inc. Reaffirms Earnings Guidance for the Full Year 2023

Executive VP & CFO exercised options and sold US$92k worth of stock

Full year 2022 earnings released: EPS: US$0.001 (vs US$0.069 in FY 2021)

Independent Director exercised options and sold US$101k worth of stock

Independent Director exercised options and sold US$114k worth of stock

Independent Director exercised options and sold US$114k worth of stock

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

InfuSystem Holdings, Inc. Revises Earnings Guidance for the Year 2022

InfuSystem Holdings, Inc. to Report Q3, 2022 Results on Nov 08, 2022

InfuSystem Holdings, Inc. Announces the Appointment of R. Rimmy Malhotra to Board of Directors, Effective September 20, 2022

Independent Director exercised options and sold US$70k worth of stock

Executive VP & Chief Commercial Officer exercised options and sold US$56k worth of stock

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

InfuSystem Holdings Inc. Revises Earnings Guidance for the Year 2022

InfuSystem Holdings, Inc. to Report Q2, 2022 Results on Aug 04, 2022

InfuSystem Holdings, Inc.(NYSEAM:INFU) dropped from Russell 2000 Dynamic Index

Independent Director exercised options and sold US$206k worth of stock

Executive VP & Chief Commercial Officer exercised options and sold US$119k worth of stock

Independent Director exercised options and sold US$66k worth of stock

InfuSystem Holdings Inc. Approves Appointment of Ralph Boyd to the Company's Board

Consensus EPS estimates fall by 38%

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

InfuSystem Holdings Inc. Provides Earnings Guidance for the Year 2022

Price target decreased to US$21.67

InfuSystem Holdings Inc., Annual General Meeting, May 17, 2022

Director exercised options and sold US$175k worth of stock

Full year 2021 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 49%

Independent Director recently bought US$107k worth of stock

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week